ideasIdea
Off-the-shelf natural killer cells to sweep up residual disease
Donor immune cells that need no matching could be given as short courses to clear the few cancer cells left after surgery, when the target is smallest.
Allogeneic natural killer and CAR-NK products have been limited by short persistence and modest activity against bulky solid tumours, but persistence matters far less when the target is a handful of disseminated cells. Combined with a cytokine support agent, repeat dosing in the molecular residual disease window is a rational use of a product class that has struggled in advanced disease.
Hypothesis
Repeat-dosed allogeneic NK cell therapy converts ctDNA-positive post-surgical patients to ctDNA-negative more often than standard care, with no cytokine release syndrome above grade 2.
Rationale
NK cells kill single cells in circulation and marrow efficiently and do not require antigen presentation or HLA matching, so they suit a low-burden, wide-antigen setting. Off-the-shelf supply makes rapid treatment after a positive test feasible.
What would test it
A phase 2 single-arm study in ctDNA-positive colorectal or breast cancer with molecular clearance at six months as primary endpoint, and paired marrow sampling to confirm disseminated cell clearance.
Maturity
preclinical evidence
Who has to act
industry
Cost to try
Medium ($1M to $50M)
Years to first evidence
7
Bottlenecks it attacks
- Dormant cells and minimal residual disease · After a 'successful' treatment, cells can sleep for years then relapse. We can barely detect them and cannot target them.
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.